Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
From the U.S. FDA-approved label for Ceftriaxone. Full label: DailyMed.
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens.
From the U.S. FDA-approved label for Ceftriaxone. Full label: DailyMed.
Ceftriaxone may be administered intravenously or intramuscularly. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site.
Directions from the U.S. FDA-approved label for Ceftriaxone — your doctor or pharmacist may advise differently.
Hypersensitivity Ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see Warnings – Hypersensitivity Reactions ). Neonates Premature neonates: Ceftriaxone for injection is contraindicated in premature neonates up to a post-menstrual age of 41 weeks (gestational age + chronological age).
Excerpt from the U.S. FDA-approved label for Ceftriaxone. Talk to a pharmacist or doctor before use.
Hypersensitivity Reactions Before therapy with ceftriaxone for injection is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agents or other drugs. This product should be given cautiously to penicillin and other beta-lactam agent-sensitive patients. Antibacterial drugs should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs.
Warnings and precautions excerpt from the U.S. FDA-approved label for Ceftriaxone — not a complete list. Talk to a pharmacist or doctor before use.
Ceftriaxone is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to ceftriaxone therapy or of uncertain etiology, were observed: Local Reactions Pain, induration and tenderness was 1% overall. Phlebitis was reported in <1% after IV administration.
Excerpt from the U.S. FDA-approved label for Ceftriaxone — not a complete list. Talk to a pharmacist or doctor about side effects.
43 brands · 18 makers in the NepalDoc catalog — see the full Ceftriaxone guide →
Prior to Reconstitution Store at 20° to 25°C (68° to 77°F). Protect from light.
Storage information from the U.S. FDA-approved label for Ceftriaxone.
What is Xone 2?
Xone 2gm Injection is a Ceftriaxone medicine made by Alkem Laboratories Ltd. It comes as 2gm Injection.
What is the generic name of Xone 2?
The generic name of Xone 2 is Ceftriaxone.
Which brands of Ceftriaxone are available in Nepal?
43 brands of Ceftriaxone are listed in the NepalDoc catalog, from 18 makers — including Accuzon 1g 1000mg Injection, Accuzon 250mg Injection, Accuzon 500mg Injection, Afrixon 2gm Injection, Blutax 1gm Injection, Cefast 1gm Injection.
What are the side effects of Ceftriaxone?
Ceftriaxone is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to ceftriaxone therapy or of uncertain etiology, were observed: Local Reactions Pain, induration and tenderness was 1% overall.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
